Company Overview and News

WA gold miners begin production

Three Western Australian gold miners have recently begun production at their respective operations, with Dacian Gold’s $200 million Mt Morgans project near Laverton pouring its first bar of gold last week.
Upvote Downvote

Dacian delivers first gold at Mt Morgans

Dacian Gold has poured its first gold bar at the $200 million Mt Morgans project in Western Australia.
Upvote Downvote

Australian gold sector posts highest annual output since 1999

Australian gold output reached its highest mark since 1999 last year, maintaining the country’s place as the world’s second largest producer behind China, the latest data from Surbiton Associates has revealed.
Upvote Downvote

RCT signs agreement with RUC Mining for tech partnership

Technology company RCT has signed an agreement with mining contractor RUC Cementation Mining to deliver new technology to RUC’s Australian and international mining sites.
Upvote Downvote

LiveHire teams with Macmahon to drive recruitment productivity

LiveHire Ltd (ASX:LVH) has successfully implemented and launched its Talent Community recruitment platform for leading mining services provider, Macmahon (ASX:MAH).
Upvote Downvote

Macmahon signs with LiveHire to meet recruitment demands

Mining services company Macmahon has launched LiveHire’s Live Talent Community technology across the company to support its growing recruitment needs for new contracts.
Upvote Downvote

Dacian delivers third Mt Morgans discovery seven weeks from first gold

Dacian Gold has confirmed the Cameron Well prospect as the “third significant gold discovery” at its Mt Morgans gold project near Laverton in Western Australia.
Upvote Downvote

Dacian Gold confirms third gold discovery at Mt Morgans project

Dacian Gold Ltd (ASX:DCN) drilling results have confirmed that Cameron Well is the third significant gold discovery at its Mt Morgans Gold Project in Western Australia.
Upvote Downvote

Demand for mining services ramps up (Part 2)

Improved commodity prices led to an increase in mining activity, meaning the expertise of the country’s mining services contractors was in growing demand.
Upvote Downvote

Demand for mining services ramps up (Part 1)

Improved commodity prices led to an increase in mining activity, meaning the expertise of the country’s mining services contractors was in growing demand.
Upvote Downvote

Dacian Gold set for March start at Mt Morgans project in WA

Dacian Gold has released an update on its 100 per cent-owned Mt Morgans gold project in Western Australia, stating that construction of the treatment facility is now 90 per cent complete and first production is set for March 2018.
Upvote Downvote

Where are Australia’s major mining projects?

The number of committed mining and energy projects in Australia has increased by 21 per cent over the past year.
Upvote Downvote

Valmec awarded $30m contracts

Energy and infrastructure contracting group Valmec has secured $30 million in new construction contracts, including a 4 kilometre gas pipeline at Dacian Gold’s Mt Morgan project.
Upvote Downvote

Macmahon secures $250m contract

Mining contractor Macmahon Holdings has secured a $250 million open pit mining contract for Dacian Gold’s Mount Morgans gold mine.
Upvote Downvote

Dacian Gold lines up Macmahon for $250m Mt Morgans contract

Macmahon Holdings has received a letter of award for a mining contract worth at least $250 million at Dacian Gold’s Mt Morgans gold operation in Western Australia.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...